Shingles jab sales rise on dementia risk reduction hopes
Shingles jab sales rise on dementia risk reduction hopes

Sales of shingles vaccines have increased following studies suggesting the jab could reduce the risk of dementia. The Guardian is asking readers who have been influenced by these findings to share their experiences.

Who is being asked to respond

The callout is aimed at people who have had the shingles vaccine in the past two years, either on the NHS or privately, because they hoped it might lower their dementia risk. The Guardian also wants to hear from those who are not eligible for the vaccine on the NHS and would like to pay for it privately but have been put off by the cost. A full course of two doses can cost around £450.

How to share your experience

Readers can share their response using the provided form. Participants must be 18 or over and can respond anonymously if they wish. Responses are secure as the form is encrypted, and only the Guardian has access to contributions. Data will only be used for the purpose of the feature and deleted when no longer required. Alternative ways to get in touch are available in the tips guide.